Nantahala Capital Management, LLC
Position in KRYS — Krystal Biotech, Inc.
CIK 1472322
New Canaan, CT
Position in KRYS
as of Jun 30, 2026
· filed Aug 19, 2026
Position Value
$0
+$0 QoQ
Shares Held
0
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2024
6 quarters on record
Derivatives in KRYS
reported options exposure · as of Jun 30, 2026CallValue
$0
CallShares
0
PutValue
$31,591,950
PutShares
85,000
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026Nantahala Capital Management, LLC holds $620,287,047 across 52 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | SVRA |
Savara Inc
|
6,976,810 | $42,977,149 | |
| 2 | AVTX |
Avalo Therapeutics, Inc.
|
1,862,250 | $34,414,380 | |
| 3 | LBRX |
Lb Pharmaceuticals Inc
|
1,052,894 | $34,171,674 | |
| 4 | ABEO |
Abeona Therapeutics Inc.
|
5,136,490 | $31,743,508 | |
| 5 | ZVRA |
Zevra Therapeutics, Inc.
|
1,797,476 | $25,775,805 | |
| 6 | MLYS |
Mineralys Therapeutics, Inc.
|
820,481 | $22,136,577 | |
| 7 | QURE |
uniQure N.V.
|
455,660 | $20,987,699 | |
| 8 | AURA |
Aura Biosciences, Inc.
|
2,951,030 | $20,952,313 |
All Filings in KRYS
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $31,591,950 | 85,000 | Put | Sole | 2026-08-19 | |
| 2025-09-30 | $35,306,000 | 200,000 | Put | Sole | 2025-11-14 | |
| 2025-06-30 | $27,492,000 | 200,000 | Put | Sole | 2025-08-14 | |
| 2024-12-31 | $7,833,000 | 50,000 | Put | Sole | 2025-02-14 | |
| 2024-09-30 | $9,811,417 | 53,900 | Put | Sole | 2024-11-14 | |
| 2024-06-30 | $716,196 | 3,900 | Put | Sole | 2024-08-14 | |
| No filing history on record for this holder in this stock. | ||||||